Expression pattern and clinical value of Key RNA methylation modification regulators in ischemic stroke

Abstract

Ischemic stroke (IS) is one of the major causes of death and disability worldwide, and effective diagnosis and treatment methods are lacking. RNA methylation, a common epigenetic modification, plays an important role in disease progression. However, little is known about the role of RNA methylation modification in the regulation of IS. The aim of this study was to investigate RNA methylation modification patterns and immune infiltration characteristics in IS through bioinformatics analysis. We downloaded gene expression profiles of control and IS model rat brain tissues from the Gene Expression Omnibus database. IS profiles were divided into two subtypes based on RNA methylation regulators, and functional enrichment analyses were conducted to determine the differentially expressed genes (DEGs) between the subtypes. Weighted gene co-expression network analysis was used to explore co-expression modules and genes based on DEGs. The IS clinical diagnosis model was successfully constructed and four IS characteristic genes (GFAP, GPNMB, FKBP9, and CHMP5) were identified, which were significantly upregulated in IS samples. Characteristic genes were verified by receiver operating characteristic curve and real-time quantitative PCR analyses. The correlation between characteristic genes and infiltrating immune cells was determined by correlation analysis. Furthermore, GPNMB was screened using the protein-protein interaction network, and its regulatory network and the potential therapeutic drug chloroquine were predicted. Our finding describes the expression pattern and clinical value of key RNA methylation modification regulators in IS and novel diagnostic and therapeutic targets of IS from a new perspective.

Machine learning and deep learning to identifying subarachnoid haemorrhage macrophage‐associated biomarkers by bulk and single‐cell sequencing

“…The GPNMB, although not previously studied in SAH, demonstrates significant upregulation in ischemic stroke 38,39 . Its potential as a therapeutic target, associated with inflammation and neuroinflammation, warrants exploration 40 .…”

“…34 The GPNMB, although not previously studied in SAH, demonstrates significant upregulation in ischemic stroke. 38,39 Its potential as a therapeutic target, associated with inflammation and neuroinflammation, warrants exploration. 40 Osteopontin (OPN), or SPP1, plays a dual role in early brain injury and delayed cerebral ischemia in aneurysmal SAH.…”